| [1] |
Chen W. Cancer statistics: updated cancer burden in China [J]. Chin J Cancer Res,2015,27(1):1.
|
| [2] |
Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021 [J]. CA Cancer J Clin, 2021, 71(1): 7-33.
|
| [3] |
Loeb S, Bjurlin MA, Nicholson J, et al. Overdiagnosis and overtreatment of prostate cancer [J]. Eur Urol, 2014, 65(6): 1046-1055.
|
| [4] |
Lambin P, Rios-Velazquez E, Leijenaar R, et al. Radiomics: extracting more information from medical images using advanced feature analysis [J]. Eur J Cancer, 2012, 48(4): 441-446.
|
| [5] |
Andreassen CN, Alsner J, Overgaard J. Does variability in normal tissue reactions after radiotherapy have a genetic basis-where and how to look for it? [J]. Radiother Oncol, 2002, 64(2): 131-140.
|
| [6] |
Li ZC, Zhai G, Zhang J, et al. Differentiation of clear cell and non-clear cell renal cell carcinomas by all-relevant radiomics features from multiphase CT: a VHL mutation perspective [J]. Eur Radiol, 2019, 29(8): 3996-4007.
|
| [7] |
Fathi Kazerooni A, Bakas S, Saligheh Rad H, et al. Imaging signatures of glioblastoma molecular characteristics: A radiogenomics review [J]. J Magn Reson Imaging, 2020, 52(1): 54-69.
|
| [8] |
Gallivanone F, Bertoli G, Porro D. Radiogenomics, breast cancer diagnosis and characterization: current status and future directions [J]. Methods Protoc, 2022, 5(5): 78.
|
| [9] |
Ferro M, de Cobelli O, Vartolomei MD, et al. Prostate cancer radiogenomics-from imaging to molecular characterization [J]. Int J Mol Sci, 2021, 22(18): 9971.
|
| [10] |
Leech M, Osman S, Jain S, et al. Mini review: personalization of the radiation therapy management of prostate cancer using MRI-based radiomics [J]. Cancer Lett, 2021, 498: 210-216.
|
| [11] |
Khalvati F, Wong A, Haider MA. Automated prostate cancer detection via comprehensive multi-parametric magnetic resonance imaging texture feature models [J]. BMC Med Imaging, 2015, 15: 27.
|
| [12] |
He D, Wang X, Fu C, et al. MRI-based radiomics models to assess prostate cancer, extracapsular extension and positive surgical margins [J]. Cancer Imaging, 2021, 21(1): 46.
|
| [13] |
Schwier M, van Griethuysen J, Vangel MG, et al. Repeatability of multiparametric prostate MRI radiomics features [J]. Sci Rep, 2019, 9(1): 9441.
|
| [14] |
Maggi M, Del Giudice F, Falagario UG, et al. SelectMDx and multiparametric magnetic resonance imaging of the prostate for men undergoing primary prostate biopsy: a prospective assessment in a multi-institutional study [J]. Cancers (Basel), 2021, 13(9): 2047.
|
| [15] |
Haffner MC, Zwart W, Roudier MP, et al. Genomic and phenotypic heterogeneity in prostate cancer [J]. Nat Rev Urol, 2021, 18(2): 79-92.
|
| [16] |
Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer [J]. Cancer Cell, 2010, 18(1): 11-22.
|
| [17] |
Rutman AM, Kuo MD. Radiogenomics: creating a link between molecular diagnostics and diagnostic imaging [J]. Eur J Radiol, 2009, 70(2): 232-241.
|
| [18] |
Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or=4.0 ng per milliliter [J]. N Engl J Med, 2004, 350(22): 2239-2246.
|
| [19] |
Norris JM, Simpson BS, Parry MA, et al. Genetic correlates of prostate cancer visibility (and invisibility) on multiparametric magnetic resonance imaging: it's time to take stock [J]. BJU Int, 2020, 125(3): 340-342.
|
| [20] |
Radtke JP, Takhar M, Bonekamp D, et al. Transcriptome wide analysis of magnetic resonance imaging-targeted biopsy and matching surgical specimens from high-risk prostate cancer patients treated with radical prostatectomy: the target must be hit [J]. Eur Urol Focus, 2018, 4(4): 540-546.
|
| [21] |
Porreca A, Del Giudice F, Giampaoli M, et al. Adding systematic biopsy to magnetic resonance ultrasound fusion targeted biopsy of the prostate in men with previous negative biopsy or enrolled in active surveillance programs: A prospective single center, randomized study [J]. Medicine (Baltimore), 2020, 99(37): e22059.
|
| [22] |
McCann SM, Jiang Y, Fan X, et al. Quantitative multiparametric MRI features and PTEN expression of peripheral zone prostate cancer: a pilot study [J]. AJR Am J Roentgenol, 2016, 206(3): 559-565.
|
| [23] |
Renard-Penna R, Cancel-Tassin G, Comperat E, et al. Multiparametric magnetic resonance imaging predicts postoperative pathology but misses aggressive prostate cancers as assessed by cell cycle progression score [J]. J Urol, 2015, 194(6): 1617-1623.
|
| [24] |
Sun Y, Williams S, Byrne D, et al. Association analysis between quantitative MRI features and hypoxia-related genetic profiles in prostate cancer: a pilot study [J]. Br J Radiol, 2019, 92(1104): 20190373.
|
| [25] |
Fischer S, Tahoun M, Klaan B, et al. A radiogenomic approach for decoding molecular mechanisms underlying tumor progression in prostate cancer [J]. Cancers (Basel), 2019, 11(9): 1293.
|
| [26] |
Liang L, Zhi X, Sun Y, et al. A nomogram based on a multiparametric ultrasound radiomics model for discrimination between malignant and benign prostate lesions [J]. Front Oncol, 2021, 11: 610785.
|
| [27] |
Wildeboer RR, van Sloun RJG, Postema AW, et al. Accurate validation of ultrasound imaging of prostate cancer: a review of challenges in registration of imaging and histopathology [J]. J Ultrasound, 2018, 21(3): 197-207.
|
| [28] |
Papadimitroulas P, Brocki L, Christopher Chung N, et al. Artificial intelligence: Deep learning in oncological radiomics and challenges of interpretability and data harmonization [J]. Phys Med, 2021, 83: 108-121.
|
| [29] |
Liu S, Wang W, Zhao Y, et al. Identification of potential key genes for pathogenesis and prognosis in prostate cancer by integrated analysis of gene expression profiles and the cancer genome atlas [J]. Front Oncol, 2020, 10: 809.
|
| [30] |
Ushinsky A, Bardis M, Glavis-Bloom J, et al. A 3D-2D hybrid U-Net convolutional neural network approach to prostate organ segmentation of multiparametric MRI [J]. AJR Am J Roentgenol, 2021, 216(1): 111-116.
|